Leste

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

Medical conventions are challenged every day. Already in the new year, the effectiveness of cold medicine and the gold standard in breast cancer treatment have been challenged. Standards in cholesterol testing are the latest casualty of medical innovation. For years, cholesterol has been measured by a simple panel o...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...

Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients

* Treatment with ISIS 301012 produced at least 45% additionalreduction in patients' LDL-cholesterol when added tomaximally-tolerated lipid-lowering therapies CARLSBAD, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- IsisPharmaceuticals, Inc. announced updated results from its ongoingPhase 2 clinical trial of ISIS 301012 in patients with homozygousfamilial hypercholesterolemia (HoFH), initi...

KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time

Research Breakthrough Will Aid in Developing Therapies to Preventand Reverse Atherosclerotic Heart Disease EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- KineMed, Inc.,a pathway-based drug discovery and development company, announcedtoday the first method for measuring the efflux of cholesterol fromtissues in animals through the pathway known as reverse cholesteroltransport (RCT). RCT i...

CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries

VICTORIA, Australia, March 27, 2007--CSL Limitedtoday announced results from a study published in the Journal ofthe American Medical Association that suggest infusions of a novelnew drug, CSL-111, to acutely raise HDL (“good”cholesterol) levels, may reduce the amount of plaque in thecoronary arteries of patients with a recent episode of acutecoronary syndrome (AC...

CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume in Coronary Arteries

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- CSL Limited todayannounced results from a study published in the Journal of theAmerican Medical Association that suggest infusions of a novel newdrug, CSL-111, to acutely raise HDL ("good" cholesterol) levels,may reduce the amount of plaque in the coronary arteries ofpatients with a recent episode of acute coronary syndrome(ACS). ACS is...

Cholesterol Drug Fails to Slow Progression of Coronary Disease, Cleveland Clinic Study Reports

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- Cleveland Clinicresearchers today report that the drug torcetrapib, despite raisinghigh density lipoprotein cholesterol (HDL) or the "good"cholesterol by more than 60%, did not slow the progression ofplaque buildup in the coronary arteries as measured using anultrasound probe. Steven Nissen, M.D., Chairman of Cardiovascular Medicine atCl...

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC

* Homozygous FH patients already being treated with maximallytolerated lipid-lowering therapies experienced 50% furtherreductions in LDL-C with similar reductions in other atherogenicwhen treated with 300 mg/week ISIS 301012 NEW ORLEANS, and CARLSBAD, Calif., March 26, 2007/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announcedresults from its ongoing Phase 2 clinical trial of ISIS...